Pharmacokinetics and cerebrospinal fluid penetration of CI-994 (N- acetyldinaline) in the nonhuman primate

Clinical Cancer Research

Volumn 6, Issue 3, 2000, Pages 994-997

  Riva, Luca ^a   Blaney, Susan M ^b   Dauser, Robert ^b   Nuchtern, Jed G ^b   Durfee, John ^b   McGuffey, Leticia ^b   Berg, Stacey L ^b,c  

^a SAN GERARDO HOSPITAL   (Italy)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c TEXAS CHILDREN S CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 N ACETYLDINALINE;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CEREBROSPINAL FLUID; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PENETRATION; MALE; NONHUMAN; PRIMATE; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; INFUSIONS, INTRAVENOUS; MACACA MULATTA; MALE; METABOLIC CLEARANCE RATE; PHENYLENEDIAMINES;

EID: 0034058081     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. LoRusso, P., Demchik, L., Foster, B., Knight, J., Bissery, M-C., Polin, L., Leopold, W., and Corbett, T. Preclinical antitumor activity of CI-994. Investig. New Drugs, 14: 349-356, 1996.
2. El-Beltagi, H., Martens, A., Lelieveld, P., Haroun, E., and Hagenbeek, A. Acetyldinaline: a new oral cytostatic drug with impressive differential activity against leukemia cells and normal stem cells - preclinical studies in a relevant rat model for human acute myelocytic leukemia. Cancer Res., 53: 3008-3014, 1993.
3. El-Beltagi, H., Martens, A., Dahab, G., and Hagenbeek, A. Efficacy of acetyldinaline for treatment of minimal residual disease (MRD): preclinical studies in the BNML rat model for human acute myelocytic leukemia. Leukemia (Baltimore), 7: 1795-1800, 1993.
4. Seelig, M., and Berger, M. Efficacy of dinaline and its methyl and acetyl derivatives against colorectal cancer in vivo or in vitro. Eur. J. Cancer, 32A: 1968-1976, 1996.
5. Berger, M., Richter, H., Seelig, M., Eibl, H., and Schmahl, D. New cytostatics - more activity and less toxicity. Cancer Treat. Rev., 17: 143-154, 1990.
6. Graziano, M., Pilcher, G., Walsh, K., Kasali, O., and Radovic, L. Preclinical toxicity of a new oral anticancer drug, CI-994 (acetyl dinaline) in rats and dogs. Investig. New Drugs, 15: 295-310, 1997.
7. Rummel, S., Kraker, A., Steinkarnpf, R., Hook, K., and Klohs, W. Role of a small molecular weight phosphoprotein in the mechanism of action of CI-994 (N-acetyldinaline). Int. J. Cancer, 62: 636-642, 1995.
8. LoRusso, P., Wozniak, A., Foster, B., Zalupski, M., Shields, A., McCormick, J., Meyer, M., Radulovic, L., and Corbett, T. Phase I clinical trial of CI994. Proc. Am. Soc. Clin. Oncol., 16: 213a, 1997.
9. Lelieveld, P., Middledorp, R., and van Putten, L. Effectiveness of P-aminobenzoyl-O-phenylenediamine (Goe 1734) against mouse, rat, and human tumour cells. Cancer Chemother. Pharmacol., 15: 88-90, 1985.
10. National Research Council. Guide for the care and use of laboratory animals. Washington, D. C.: National Academy Press, 1996.
11. McCully, C., Baus, F., Bacher, J., Phillips, J., and Poplack, D. A rhesus monkey model for continuous infusion of drugs into cerebrospinal fluid. Lab. Anim. Sci., 40: 522-525, 1990.
12. Foster, B., Jones, L., Wiegand, R., LoRusso, P., and Corbett, T. Preclinical pharmacokinetic, antitumor and toxicity studies with CI-994 (N-acetyldinaline). Investig. New Drugs, 15: 187-194, 1997.
13. Knott, G. MLAB - a mathematical modeling tool. Comput. Programs Biomed., 10: 271-280, 1979.
14. Yamaoka, K., Nakagawa, T., and Uno, T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm., 6: 165-175, 1978.
15. Perrier, D., and Mayersohn, M. Noncompartmental determination of the steady-state volume of distribution for any mode of administration. J. Pharm. Sci., 71: 372-373, 1982.
16. CI-994 Investigator's Brochure. Ann Arbor, MI: Parke-Davis Pharmaceutical Research, Division of Warner Lambert Co., 1994.
17. D'Argenio, D., and Schumitzky, A. ADAPT II User's Guide, Vol. 9, pp. 115-134. Los Angeles: Biomedical Simulations Resource, University of Southern California, 1992.
18. Berg, S., Balis, F., and Poplack, D. Cancer chemotherapy. In: D. Nathan and S. Orkin (eds.), Nathan and Oski's Hematology of Infancy and Childhood, Vol. 2, pp. 1201-1232. Philadelphia: W. B. Saunders, 1998.